NeuroSense Therapeutics, Ltd. (NRSN): Fair Value Consensus
The market capitalization trend of NeuroSense Therapeutics (NRSN) demonstrates the company's potential pricing power within the CNS therapy segment, where demand remains inelastic due to the innovative PrimeC capsules. Development focuses on combating ALS, with expectations for a breakthrough in clinical trials and the attainment of orphan drug status, which constitutes 100.82. However, high research expenditures and uncertainty regarding trial outcomes create significant financial risks.
Analytical breakdowns for NeuroSense Therapeutics (NRSN)
- stock price and consensus target price:
- stock exchange capitalization data:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Debt to Equity Ratio NeuroSense Therapeutics|NRSN - Long-Term Debt to Capital|Current Liabilities to Capital neurosense-tx.com|NRSN - Company Total Debt|Debts to Book Capitalization NeuroSense Therapeutics, Ltd.|NRSN - Company Long-Term Debt|Company Short-Term Loans and Borrowings NeuroSense Therapeutics|Immediate Liquidity neurosense-tx.com
- net income and valuation ratios data:
NRSN - Company Net Income|Net Profit Forecast NeuroSense Therapeutics|NRSN - P/E Multiple|Projected Price to Earnings Ratio neurosense-tx.com|NRSN - Price/Earnings to Growth Multiple|EV/EBITDA Multiple NeuroSense Therapeutics, Ltd.|NRSN - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year NeuroSense Therapeutics|NRSN - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months neurosense-tx.com|NRSN - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year NeuroSense Therapeutics
Summary company analytics:NRSN NeuroSense Therapeutics Ltd
This indicator reflects the aggregate expert expectation regarding the asset's market value, measuring the balance of supply and demand through the lens of the company's management efficiency. By analyzing the consensus price target, the investor assesses the probability of capitalizing on the successes of NeuroSense Therapeutics (NRSN), where the precision of chemical component logistics for neurotherapy directly impacts research schedule adherence and the final fundamental valuation.
Competitors of NeuroSense Therapeutics
biogen.com - Broker Consensus Forecast|Price Target Chart Neurocrine Biosciences, Inc. NBIX|Fair Value Consensus RGC|AXSM - Price Target Chart|Analyst Median Target ACADIA Corp ACAD|Xenon Pharmaceuticals (XENE) - Price Target Chart|Broker Consensus Forecast VKTX|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|Price Target Chart Prothena Corporation PLC|Broker Consensus Forecast ALEC (Alector Therapeutics)|Analyst Consensus Forecast ANNX|OMER - Average Forecast Price|Neurogene Corp - Consensus Target|Analyst Consensus Forecast AC Immune Inc ACIU|VYGR - Price Target Chart|Fair Value Consensus NMRA (neumoratx.com)|Scilex (SCLX) - Price Target Chart|Average Forecast Price Tevogen Bio Holdings Inc. (TVGN)|Price Target Chart Alpha Cognition Inc|cogrx.com (CGTX) - Analyst Median Target|Analyst Consensus Forecast IKT|SAVA - Average Forecast Price|Price Target Chart Assertio ASRT|COYA: Broker Consensus Forecast|VTGN - Price Target Chart|Analyst Median Target Ovid Therapeutics Inc. OVID|ABOS: Analyst Consensus Forecast|Average Forecast Price cervomed.com (CRVO)|Consensus Target ATHE|CLNN: Fair Value Consensus|Consensus Target PEPG (PepGen Inc.)|Analyst Forecast Prices JUNS|Analyst Consensus Forecast RLMD (Relmada Therapeutics)|Fair Value Consensus ANVS|Grace Tx - Analyst Consensus Forecast|Average Forecast Price Firefly Neuroscience, Inc.|anewmeds.com (KLTO) - Price Target Chart|Reviva Pharmaceuticals, Inc. - Fair Value Consensus|MTVA (MetaVia Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast neuraxis.com|Price Target Chart Helius Medical (HSDT)|PASG: Forecast Levels Chart|Analyst Consensus Forecast NEUP (Neuphoria Therapeutics)|Minerva (NERV) - Average Forecast Price|ATHA: Consensus Target|ADXN - Analyst Consensus Forecast|ALZN (alzamend.com) - Consensus Target|CYCN: Analyst Forecast Prices|PTIX (Protagenic Therapeutics Inc.) - Analyst Consensus Forecast|Pasithea (KTTA) - Analyst Median Target|Analyst Consensus Forecast CRGT|Consensus Target avenuetx.com ATXI|Price Target Chart BrainStorm Cell Therapeutics BCLI|Analyst Median Target Cara Therapeutics Inc. (CARA)|CHRO - Price Target Chart|ELYM (Eliem Therapeutics) - Broker Consensus Forecast|intracellulartherapies.com (ITCI) - Price Target Chart|longboardpharma.com - Fair Value Consensus|Price Target Chart Marinus Pharmaceuticals, Inc.|NKGen Biotech Inc (NKGN) - Analyst Median Target|Price Target Chart NeuroBo (NRBO)|Sage Therapeutics Inc - Broker Consensus Forecast|Price Target Chart Synaptogenix, Inc. SNPX|TRVN: Broker Consensus Forecast|Vigil Neuro - Analyst Consensus Forecast|Average Forecast Price Anew Medical Inc.|CERE (Cerevel) - Consensus Target
